Arcturus Therapeutics Holdings Inc（ARCT）财务数据ARCTArcturus Therapeutics Holdings Inc

Evaluating the bottom line, Arcturus Therapeutics Holdings Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -863.30%, while the net margin is -803.82%. These profitability ratios, combined with a Return on Equity (ROE) of -46.31%, provide a clear picture of how effectively ARCT converts its operational activities into shareholder value.

In the context of the broader market, ARCT competes directly with industry leaders such as CMPX and AVIR. With a market capitalization of $461.16M, it holds a leading position in the sector. When comparing efficiency, ARCT's gross margin of 100.00% stands against CMPX's N/A and AVIR's N/A. Such benchmarking helps identify whether Arcturus Therapeutics Holdings Inc is trading at a premium or discount relative to its financial performance.

The company's gross margin remains strong at 100%, but it has been reporting consistent net losses, with a net income of -$23.8 million in Q2 2026 and an EPS of -0.84.